Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Condition(s):Relapsed/Refractory Peripheral T-cell LymphomaLast Updated:January 31, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Peripheral T-cell LymphomaLast Updated:January 31, 2023Recruiting
Condition(s):Early-stage; Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:December 8, 2021Recruiting
Condition(s):Immune Checkpoint Inhibitor; Chemotherapy Effect; Epigenetic Disorder; NK/T-cell Lymphoma of Nasal CavityLast Updated:July 7, 2020Recruiting
Condition(s):Relapsed or Refractory DLBCLLast Updated:April 7, 2022Not yet recruiting
Condition(s):MSS; pMMR; Metastatic Colorectal AdenocarcinomaLast Updated:October 5, 2021Unknown status
Condition(s):Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type; Early-stage; High-Risk CancerLast Updated:February 24, 2022Recruiting
Condition(s):Advanced Solid TumorsLast Updated:May 16, 2019Unknown status
Condition(s):Hodgkin LymphomaLast Updated:September 10, 2018Completed
Condition(s):Metastatic Colorectal AdenocarcinomaLast Updated:July 12, 2023Completed
Condition(s):Endometrial CancerLast Updated:November 8, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.